Introduction
Cholesterol is the archetypical sterol, being an essential component of cell membranes throughout the animal kingdom [1] . The first step of cholesterol metabolism is oxidation to an oxysterol [2] . Similarly, precursors of cholesterol can be oxidised to oxysterols [3] . Consequently, oxysterols are a large family of molecules where cholesterol or its precursors have additional oxygen functionalities at one or more positions in the ring system or on the side-chain. Oxysterol analysis dates back to the 1940s and even at that time the potential of cholesterol to undergo nonenzymatic oxidation ex vivo was noted [4] . This can be problematic as cholesterol can be oxidised in air to give identical products to some of those formed enzymatically. Throughout the years, from the 1940s onwards, there have been many reports where oxysterols formed by nonenzymatic autoxidation ex vivo have been confused by those formed enzymatically in vivo [2] . The situation is further complicated by the fact that oxysterols can be formed endogenously by reactive oxygen species (ROS) [5, 6] with the same structures as those formed ex vivo or enzymatically e.g. 7-oxocholesterol (7-OC), 7b-hydroxycholesterol (7b-HC) [7, 8] . Oxysterols are key members of the bile acid and steroid hormone biosynthesis pathways [9] . Mutations in enzymes responsible for oxysterol formation can lead to disease in humans. One example is cytochrome P450 (CYP) 27A1, a sterol (25R) 26-hydroxylase, whose deficiency is the cause of cerebrotendinous xanthomatosis (CTX), a rare disease which can present in early infancy with cholestatic liver disease [10] , in early childhood with chronic diarrhoea and cataracts, in later childhood with tendon xanthomata, learning difficulties or psychiatric illness, and in adult life with spastic paraparesis, a fall in IQ or frank dementia, ataxia and/or dysarthria [11] . CTX is usually diagnosed only in the adolescent and adult. Deficiency in another enzyme, CYP7B1, an oxysterol 7a-hydroxylase, can lead to liver disease in infants and spastic paraplegia in adults (hereditary spastic paraplegia type 5, SPG5) [12] . Deficiency in CYP7A1, cholesterol 7a-hydroxylase, can lead to hyperlipidemia and gallstones [13] . The brain contains a high proportion of the body's cholesterol [1] , the majority of which is present in myelin sheaths of oligodendrocytes but much of cholesterol metabolism is in neurons where CYP46A1 oxidises it to 24S-hydroxycholesterol (24S-HC) [14] . Unlike cholesterol, 24S-HC can pass the blood brain barrier (BBB) and be exported from brain [15] . This makes 24S-HC a target for analysis in plasma in the hope of early diagnosis of neurodegenerative disease e.g. Alzheimer's disease (AD), Parkinson's disease (PD) [16, 17] .
Oxysterol synthesis is an important part of the immune response to pathogens. Macrophages, a type of white blood cell which play a critical role in immunity can make high levels of 25-hydroxycholesterol (25-HC), through up-regulation of cholesterol 25-hydroxylase (CH25H), when stimulated by bacteria [18, 19] or viruses [20] , and its metabolite 7a,25-dihydroxycholesterol (7a,25-diHC) can activate a G protein-coupled receptor (GPCR) called Epstein-Barr virus-induced gene 2 (EBI2, GPR183) and oxysterol gradients guide migration of EBI2 expressing immune cells [21, 22] many of which have been implicated in shaping the adaptive and innate immune response. The exact role of 25-HC itself in immunity is yet to be uncovered, although Reboldi et al. showed that 25-HC is a mediator of negative feedback towards interleukin 1 (IL-1) family cytokine production and inflammasome activity, through binding to INSIG (insulin induced gene) and antagonising the sterol response element-binding protein-2 (SREBP-2) driven mevalonate pathway, thereby, reducing Il1b transcription and repressing IL-1-activating inflammasomes [23] .
Most recently, oxysterols have been implicated in neurogenesis [24] and their relatives, cholestenoic acids, in the regulation of survival of motor neurons [25] . Their involvement in these processes is through interaction with the liver X receptors (LXRs), known receptors of oxysterols [26, 27] .
Metabolism of cholesterol and its precursors to oxysterols

Enzymatic metabolism of cholesterol
The first step in steroid hormone biosynthesis is oxidation of cholesterol to 22R-hydroxycholesterol (22R-HC) and on to 20R,22R-dihydroxycholesterol (20R,22R-diHC) and ultimately to pregnenolone by the enzyme CYP11A1 [28] . Interestingly, 22R-HC and 20R,22R-diHC have been reported to be present in newborn and adult mouse brain supporting the concept to steroidogenesis in brain [29, 30] (Fig. 1A, Supplementary Table S1 ). Both these oxysterols activate LXRs [28] . The first step of the neutral pathway of bile acid biosynthesis is oxidation of cholesterol to 7a-hydroxycholesterol (7a-HC) by hepatic CYP7A1, 7a-HC is then oxidised to 7a-hydroxycholest-4-en-3-one (7a-HCO) by hydroxysteroid dehydrogenase (HSD) 3B7 or alternatively 7a-HC is further hydroxylated to 7a,(25R)26-dihydroxycholesterol (7a, (25R)26-diHC) by CYP27A1 (Fig. 1B) . Note, introduction of a hydroxy group at the terminal carbons, C-26 or C-27, of the cholesterol side-chain introduces R or S stereochemistry at C-25. To avoid confusion we define the stereochemistry when known, and use the systematic numbering of carbon atoms according to IUPAC rules [31] . 7a-HCO can be similarly hydroxylated by CYP27A1 and 7a,(25R)26-diHC can be oxidised by HSD3B7, both to give 7a,(25R)26-dihydroxycholest-4-en-3-one (7a,(25R)26-diHCO). Alternatively, hydroxylation can be at C-12a through CYP8B1 to generate 7a,12a-dihydroxycholest-4-en-3-one (7a,12a-diHCO) on the pathway to cholic acid, and oxidation of both 7a,12a-diHCO and 7a,(25R)26-diHCO by CYP27A1 can occur to generate the (25R)26 acids, 7a,12a-dihydroxy-3-oxocholest-4-en-(25R)26-oic (7a,12a-diH,3O-CA) and 7a-hydroxy-3-oxocholest-4-en-(25R)26-oic (7aH,3O-CA) acids, respectively. Each of these metabolites can be observed in human and in mouse plasma (Table 1, Table S1 ) [32] [33] [34] [35] [36] . Prior to formation of (25R)26 acids the 3-oxo-4-ene group can be reduced by two successive aldoketo reductase (AKR) enzymes, 1D1 and 1C4, to a 3a-hydroxy-5b-hydrogen configuration, but metabolites with these structures are not routinely observed in plasma. Of the enzymatically formed oxysterols, 7a-HC can also be formed by autoxidation of cholesterol ex vivo, so there is always a concern over concentration reported in the literature for this oxysterol [2] . The first step of the acidic pathway of bile acid biosynthesis is the conversion of cholesterol to (25R)26-hydroxycholesterol ((25R)26-HC) by CYP27A1 (Fig. 1B) . (25R)26-HC can be oxidised further to the (25R)26 acid, 3b-hydroxycholest-5-en-(25R)26-oic acid (3b-HCA), by CYP27A1 or to 7a,(25R)26-diHC by CYP7B1. Both of these metabolites can be converted to 3b,7a-dihydroxycholest-5-en-(25R)26-oic acid (3b,7a-diHCA) or alternatively 7a,(25R)26-diHC can be oxidised to 7a,(25R)26-diHCO by HSD3B7. 7a,(25R)26-diHCO is then further oxidised to 7aH,3O-CA by CYP27A1 while is 3b,7a-diHCA is oxidised by HSD3B7 also to 7aH,3O-CA. While the neutral pathway of bile acid biosynthesis is hepatic, the acidic pathway can proceed extrahepatically [37] . (25R)26-HC is largely biosynthesised in lung [38] . Both 7a,(25R)26-diHCO and 7aH,3O-CA are exported from brain while (25R)26-HC is imported to brain from the circulation indicating that the bile acid biosynthesis [60] , n = 3 independent sample preparations, mean AE SD. i From McDonald et al. [35] . j From Quehenberger et al. [69] , n = 3, mean AE SE. k From McDonald et al. [35] , n = 200, mean AE RSE. l From Stiles et al. [36] , n = 3230, median (range). m From Honda et al. [73] , n = 19, mean AE SD. n From van de Merbel [108] , n = 129, mean AE SD. o From Ikegami et al. [109] , n = 36, mean AE SE. p From Burkard et al. [71] , n = 22, mean AE SD. q From Jiang et al. [77] , n = 89, mean(range). r From Bandaru et al. [70] , n = 12, mean AE SD. s From Ikegami et al. [74] , n = 113, mean AE SE. t From Sidhu et al. [75] , pooled plasma sample. u From DeBarber et al. [79] , n = 20, mean AE SD. v From DeBarber et al. [80] , n = 9, mean AE SD. w From Bodin et al. [110] , n = 125, mean AE SD. x From Dzeletovic et al. [40] , n = 31, mean AE SD, free oxysterol levels re-calculated from% of unesterified oxysterols (n = 6). y From Axelson and Sjövall [111] , n = 20, median (upper quartile-lower quartile) for acids, n = 6 for hydroxysterols average (range). z From Meaney et al. [39] , n = 9, mean AE SE, blood taken from brachial artery, values not significantly different from the jugular vein except of 7a-hydroxy-3-oxocholest-4-enoic acid which is elevated by 2.8 AE 1.3 ng/mL in venous blood. 7a-Hydroxycholest-4-en-3-one measured by LC-UV.
A From Axelson et al. [37] , n = 11, mean AE SD. B From Schött et al. [65] , representative plasma sample, mean AE SD, n = 6 measurements. C From Ogundare et al. [95] , n = 9, mean AE SD. D From Theofilopoulos et al. [25] , pool of 15CSF samples, mean AE SE, n = 3 measurements. E From Theofilopoulos et al. [25] , n = 18, mean AE SE. F From Sidhu et al. [75] , pooled CSF sample. G From Leoni et al. [63] , n = 24, median (25-75% confidence interval). H From Saeed et al. [68] , n = 8, mean AE SD.
pathway is active in brain [34, 39] . All of the above metabolites of the acidic pathway of bile acid biosynthesis are observed in human plasma [32, 34, 36] . In plasma oxysterols are found predominately esterified to fatty acids, the ratio of esterified to free oxysterols is of the order of about 10:1 [40] . The major oxysterol exported from brain is 24S-HC, this is metabolised in liver to 7a,24S-dihydroxycholesterol (7a,24S-diHC) by CYP39A1 and further to 7a,24S-dihydroxycholest-4-en-3-one (7a,24S-diHCO) ( Fig. 2A ) [9] . Low levels of 7a,24S-diHC or 7a,24S-diHCO have been observed in mouse cerebrospinal fluid (CSF) ( Table S1 ) [33] , and we have recently identified 7a,24S-diHCO in mouse and porcine brain [Griffiths, unpublished data] . Cyp39a1 is reported to be expressed in the somatosensory cortex of adult mouse brain [41] . The Allen Brain Atlas [41] , http://www.brainmap.org/, is an excellent resource for gene expression data in brain. An alternative route of metabolism of 24S-HC is through conjugation with sulphuric and/or glucuronic acids and excretion in urine [42, 43] . 25-HC is usually present at low levels in biological samples ( Table 1, Table S1 ). As is the case with 7a-HC, it can be formed enzymatically and by autoxidation, and again there is always doubt whether the 25-HC observed is formed in vivo or ex vivo during sample handling or storage [2] . High levels of 25-HC are formed by macrophages following bacterial or viral challenge, in which case plasma levels are elevated [18] [19] [20] . 25-HC is metabolised by CYP7B1 to 7a,25-diHC and on to 7a,25-dihydroxycholest-4-en-3-one (7a,25-diHCO) by HSD3B7 (Fig. 2B) .
Recently it was reported by Nelson et al. [44] and by Wu et al. [45] that (25R)26-HC (commonly referred to by the nonsystematic name 27-hydroxycholesterol) is associated with ERpositive breast cancer. Earlier studies had established (25R)26-HC as a selective estrogen receptor modulator [46] and Nelson et al. showed that (25R)26-HC increased ER-dependent growth and LXR-dependent metastasis in a mouse model of breast cancer [44] . High grade tumours, tumour cells and tumour associated macrophages were found to express high levels of CYP27A1 [44] . Wu et al. [45] found that the (25R)26-HC content of normal breast tissue was increased in ER+ breast cancer patients compared to cancer-free controls, and in tumours (25R)26-HC was further elevated. Both Nelson et al. and Wu et al. found that increased (25R )26-HC concentrations correlated with reduced expression of CYP7B1, the enzyme responsible for metabolism of (25R)26-HC to 7a,(25R)26-diHC [44, 45] . It is now timely for detailed studies of the oxysterolome in relation to cancer in general and breast cancer in particular. 
Enzymatic metabolism of cholesterol precursors
7-OC is a notorious autoxidation product [2] , however, it has recently been shown that it can be formed from the cholesterol precursor 7-dehydrocholesterol (7-DHC) by the enzyme CYP7A1 [8] . 7-OC can be metabolised by HSD11B1 to 7b-hydroxycholesterol (7b-HC) [47] . 7b-HC can also be formed by autoxidation and is another oxysterol that can be formed endogenously and ex vivo (Fig. 2C) .
24S,25-Epoxycholesterol (24S,25-EC) is an unusual oxysterol in that it is formed via a shunt of the cholesterol biosynthesis pathway, also known as the mevalonate pathway (Fig. 3) [48] . In the cholesterol synthesis pathway, prior to cyclisation to lanosterol, squalene is oxidised to 2,3S-oxidosqualene (squalene-2,3S-epoxide) by squalene epoxidase (SQLE). SQLE can introduce a second oxygen atom with the formation of 2,3S;22S,23-dioxidosqualene. 2,3S;22S,23-Dioxidosqualene is then cyclised by lanosterol synthase (LSS) to give 24S,25-epoxylanosterol. Lanosterol itself is metabolised through multiple enzymes to cholesterol, while 24S,25-epoxylanosterol follows a parallel pathway, but with the exclusion of the enzyme 24-dehydrocholesterol reductase (DHCR24), to give 24S,25-EC as the ultimate product [49] . Recently, it has been reported that 24S,25-EC can also be formed from desmosterol by CYP46A1 [50] . 24S,25-EC is a ligand to the LXRa and LXRb nuclear receptors [24, 26, 27] . It is a prominent oxysterol in developing and newborn brain, where levels of 24S-HC are low, (Table S1) [24, 51, 52] and has been ascribed neurogenerative properties in the ventral midbrain [24] . Evidence from the Cyp7b1 knockout mouse where 24S,25-EC levels are elevated in brain indicates that 24S,25-EC is metabolised through 7a-hydroxylation by CYP7B1 [52] . Interestingly, levels of 24S,25-EC are reduced in the Cyp46a1 knockout mouse both in brain and plasma [30] , [Griffiths unpublished data] , while elevated in the CYP46A1 over expressing mouse [Griffiths unpublished data] . These observations may be explained by 24S,25-EC being formed from desmosterol by CYP46A1 or alternatively through differential regulation of the mevalonate pathway by negative-feedback by cholesterol whose synthesis along with that of desmosterol is reduced in brain of the Cyp46a1 knockout mouse in response to its reduced metabolism [30, 53] . 24S,25-EC is technically difficult to analyse as it is susceptible to acid catalysed hydration and methanolysis.
Besides being a substrate for CYP46A1, desmosterol is also a substrate for CYP7A1 and CYP27A1 with the formation of 7a-hydroxydesmosterol (7a-HD) and 26-hydroxydesmosterol (26-HD), respectively (Table S1 ) [29, 54] .
Metabolism via reactive oxygen species
7-OC, 7a-HC, 7b-HC, 5a,6a-epoxycholesterol (5a,6a-EC) and 5b,6b-EC have been proposed to be formed via ROS in vivo while cholestane-3b,5a,6b-triol (3b,5a,6b-triol) is formed from 5,6-EC by the enzyme cholesterol epoxide hydrolase (ChEH). As the in vivo ROS-formed sterols can also be formed from cholesterol ex vivo analysis is challenging [55] . Both 7-OC and 3b,5a,6b-triol have been linked to the lipid storage disease Niemann-Pick disease type C1 (NPC1) (Fig. 4 ). An alternative mechanism for metabolism of 5a,6a-EC is aminolysis with histamine to give dendrogenin A (DDA, Fig. 4 ). Low levels of endogenous DDA are found in brain and also in other tissues and plasma [56] . DDA is not detected in cancer cell lines and is present at lower concentrations in breast tumours than normal tissue suggesting that DDA may be deregulated during carcinogenesis [56, 57] .
Classical analytical methods
Avoiding ex vivo autoxidation
Whether the ultimate analytical method is gas chromatography-mass spectrometry (GC-MS) or liquid chromatography (LC)-MS precautions need to be taken to minimise ex vivo autoxidation. For example, for plasma or serum analysis collection of blood into EDTA containing vacutainers is preferred, EDTA chelates Fe 2+ and thereby prevents Fenton chemistry and the generation of free radicals. Following centrifugation to prepare e.g. plasma/serum the antioxidant butylated hydroxytoluene (BHT) is often added. An alternative is to add the peroxide reducing agent triphenylphosphine (TPP) in addition to BHT [58] . To minimise oxidation from atmospheric oxygen sample preparation steps can be performed under Ar. The precautions taken in the authors laboratory to minimise ex vivo autoxidation are to separate sterols from oxysterols in a first step of sample preparation, thereby minimising cholesterol and 7-DHC ex vivo autoxidation artefacts at source, and to perform all drying steps under vacuum. 
Gas chromatography-mass spectrometry (GC-MS)
The classical method for oxysterol analysis is by GC-MS. The limitation of this method is that it is not applicable to oxysterol conjugates, requiring hydrolysis of fatty acid esters, solvolysis of sulphates, and hydrolysis of glucuronic acid acetals. Never-theless, GC-MS provides the "gold standard" method for oxysterol analysis [60] . The "gold standard" method originates from studies in the laboratory of Björkhem and Diczfalusy and is described in the classic publication by Dzeletovic et al. [40] . This methodology has been adopted by many groups worldwide [61] [62] [63] [64] [65] . In brief, the method for plasma analysis is as follows. Blood is collected in EDTA containing vacutainers, and following centrifugation to prepare plasma, antioxidant BHT is added as are deuterated internal standards. Alkaline hydrolysis is performed under argon using 0.35 M ethanolic KOH for 2 h at room temperature. The solution is neutralised with phosphoric acid and sterols extracted into chloroform. Solvent is evaporated and the residue dissolved in toluene. Oxysterols are then separated from cholesterol on a silica (A) cartridge, eluted and dried down and derivatised to trimethylsilyl (TMS) ethers with pyridine/hexamethyldisilazane/trimethylchlorosilane (3:2:1, v/v/v) at 60 C for 30 min (Fig. 5A) . The product is dried down and re-dissolved in hexane for injection onto GC-MS. Analysis is usually by selected ion monitoring (SIM) on a single quadrupole MS. This method with minor modifications is also applicable to analysis of CSF [63] , brain tissue [66] and cells [67] . Sensitivity is of the order of 1 ng/mL from 0.5 mL of CSF [63] and <0.5 ng/mL from 0.5 mL of serum [65] .
Björkhem and colleagues have modified their GC-MS method so that it is also applicable to cholestenoic acids, specifically 7aH,3O-CA in CSF [68] . Cholestenoic acids are extracted from CSF into ether following acidification with 0.1 M HCl. After washing of the ether phase with water until neutral the ether is evaporated and the cholestenoic acids methylated with TMS-diazomethane in hexane in a solution of methanol and toluene (Fig. 5B) . After 5 min the solvent and excess reagent is removed by evaporation. The methylated acids are converted to TMS ethers as above and analysed by GC-MS. The method is sufficiently sensitive to detect ng/mL concentrations of 7aH,3O-CA from 1 mL of CSF [68] . An important consideration for sterols with a 3-oxo-4-en-7-ol group is the lability of the hydroxy group both in acid and base solution. This precludes the use of an alkaline hydrolysis step and requires careful use of any acids. To correct for any loses by dehydration Saeed et al. [68] included an isotope labelled version of 7aH,3O-CA during sample preparation.
Newer analytical methods
Liquid chromatography-mass spectrometry (LC-MS) without derivatisation
McDonald, Russell and co-workers have developed a high throughput LC-MS method for oxysterol analysis [35, 69] and most impressively implemented the method in the analysis of 3230 serum samples from a clinically well-defined cohort, the Dallas Heart Study ( Table 1 ) [36] . Their method is as follows. In brief, sterols and oxysterols are extracted into dichloromethane/methanol (1/1, v/v) containing BHT and deuterated internal standards. Following centrifugation the supernatant is hydrolysed with KOH in dichloromethane/methanol (1/1, v/v) for 1.5 h at 35 C. PBS is added to give a two phase system and the organic phase retained. Solvent is evaporated and the residue re-dissolved in hexane and sterols and oxysterols separated from other lipids on an aminopropyl cartridge. The sterol and oxysterol fraction is reconstituted in 90% methanol for injection on a reversed phase LC column. McDonald and Russell use a Poroshell 120 SB-C 18 HPLC column (150 Â 2.1 mm, 2.7 mM particle size) and an acetonitrile/propan-2-ol/5% ammonium acetate gradient. Detection is by electrospray ionisation (ESI) tandem mass spectrometry (MS/MS) exploiting multiple reaction monitoring (MRM) [35] The sensitivity of the method allows the detection of 1 ng/mL oxysterol from 200 mL of plasma. McDonald and Russell using this method analysed a pooled plasma sample from NIST representative of the population of the USA (NIST Standard Reference Material (SRM) 1950) [35, 69] and reported the concentrations of 10 oxysterols (Table 1) . Using this method they went on to analyse 3230 samples from the Dallas Heart Study. The method is applicable to >60 sterols and vitamins D metabolites, and they routinely quantified 29 sterols including 15 oxysterols in serum [36] . There are numerous other LC-MS protocols for oxysterol analysis [70] [71] [72] , but none are as extensive as that developed by McDonald and Russell or have been exploited on such a high numbers of samples [36] .
2 LC-MS with derivatisation
Although the LC-MS method described above can be used on a high throughput format, 50 samples could be extracted in a single day [35] In an effort to improve signal, derivatisation methods have been designed which in some cases also provide added structural information.
Derivatisation to picolinyl esters
Honda et al. [73] have developed a sensitive LC-MS/MS method exploiting derivatisation of oxysterols to picolinyl esters which is applicable to 5 mL of serum (Fig. 5C ). Alkaline hydrolysis (1 N KOH at 37 C, 1 h) is carried out after the addition of BHT and isotope labelled standards, then oxysterols are extracted into n-hexane. To the dried extract, freshly prepared derivatisation mixture of 2-methyl-6-nitrobenzoic anhydride (1 mg), 4-dimethylaminopyridine (3 mg), picolinic acid (8 mg), pyridine (150 mL) and triethylamine (20 mL) is added. After heating for 60 min at 80 C, the derivatised oxysterols are extracted into n-hexane and separated from insoluble material by centrifugation. The supernatant is dried down and reconstituted into acetonitrile for LC-ESI-MS/MS analysis using a Hypersil Gold (150 Â 2.1 mm, 3 mm particle size) [74] have subsequently exploited their method in the investigation of a large cohort of patients with hepatitis C virus infection (n = 55) and healthy controls (n = 113). They determined the serum concentration of 6 oxysterols and found that the levels of 7a-HC, 4b-hydroxycholesterol (4b-HC) and 25-HC were elevated in patient samples. The concentrations of these oxysterols fell after treatment with anti-viral therapy. In contrast the concentrations of 24S-HC, 26-HC and 7a-HCO did not vary between patient and control samples.
Derivatisation to nicotinyl esters
Nicotinic acid (pyridine-3-carboxylic acid) has a very similar structure to picolinic acid (pyridine-2-carboxylic acid) and has been used as a derivatisation reagent by Sidhu et al. to measure free 24S-HC in plasma and CSF (Fig. 5D) 
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formic acid buffer and oxysterols extracted into methyl-tertbutylether (MTBE). Likewise for CSF, internal standards are added to CSF (200 mL) and oxysterols extracted into MTBE. The MTBE is evaporated and a derivatisation mixture consisting of 63 mg N,N -diisopropylcarbodiimide, 62 mg nicotinic acid, and 61 mg of 4-(dimethylamino) pyridine in chloroform added. After heating at 50 C for 1 h, chloroform is evaporated and the residue re-dissolved in methanol for LC-ESI-MS/MS analysis. Sidhu et al. used a trap column (Phenomenex C 18 , 4 Â 3 mm) prior to an analytical column (Eclipse XDB-C 18 , 3 Â 100 mm, 3.5 mm particle size), both reversed phase, and a water/acetonitrile/methanol/0.1% formic acid gradient [75] . From 50 mL of plasma and 200 mL of CSF they were able to detect and quantify 24S-HC at 1 ng/mL and 0.025 ng/mL concentrations, respectively. They indicate that they have analysed over 1700 samples using this method, but in their 2015 publication just gave data for three patient samples, one pooled plasma sample and one pooled CSF sample [75] . The pooled plasma sample had a 24S-HC concentration of 8.64 ng/mL while the pooled CSF concentration was 0.244 ng/mL. These values are in moderate agreement with earlier data for free 24S-HC determined by others, see Table 1 . Very interestingly, when CSF was analysed from patients suffering from NPC1 disease, a lysosomal storage disorder, who were administered HP-b-CD intracerebroventricularly as part of a clinical trial in NPC1 patients the CSF level of 24S-HC increased 20-50 fold [75] .
Derivatisation to N,N-dimethylglycine esters
Jiang and Han have also utilised derivatisation to improve the LC-MS/MS analysis of oxysterols (Fig. 5E) [76, 77] . They exploited derivatisation to N,N-dimethylglycine esters and APCI. In brief, oxysterols are extracted from plasma (50 mL) into methanol containing internal standards and after centrifugation to remove proteins the extract is dried down. The derivatisation mixture to the loss of dimethylglycine and to protonated dimethylglycine, respectively. Jiang et al. [77] have used this method for the analysis of plasma from patients suffering from NPC1 disease. They used MRM analysis to quantify 7-OC and 3b,5a,6b-triol from control (n = 89), heterozygotes (n = 45) and homozygous NPC1 patients (n = 109). For 7-OC they found remarkably large differences in the three groups rising from 29 ng/mL in controls to 43.8 ng/mL in heterozygotes to 229 ng/mL in NPC1 patients. 3b,5a,6b-Triol was similarly increased in NPC1 patients. Although 7-OC can be formed by ex vivo autoxidation of cholesterol and no attempt was made to remove cholesterol during sample workup, the difference in [107] are shown in Supplementary Fig. S1 . concentration for both target analytes in NPC1 and controls is striking.
Derivatisation to oximes
A number of oxysterols posses a carbonyl group, e.g. 7a-HCO, 7a,12a-diHCO as does the acid 7aH,3O-CA. Carbonyl groups will react with hydroxylamine-based reagents to give oximes. This reaction has been exploited for decades in GC-MS and LC-MS studies of oxosteroids [78] . Recently, DeBarber et al. have utilised the O-(3-trimethylammonium-propyl) hydroxylamine reagent, also called quaternary amonoxy (QAO) reagent, to derivatise oxysterols possessing an oxo group [79, 80] (Fig. 5F ). They exploited this method for the diagnosis of patients with CTX. CTX is a disease resulting from sterol (25R)26-hydroxylase (CYP27A1) deficiency.
Derivatisation is simple; QAO reagent (210 mg) is added in methanol containing 5% acetic acid to 4 mL of plasma or to a dried blood spot, after 2 h at room temperature the mixture is analysed by LC-ESI-MS/MS exploiting the MRM transition [M] + ! 152 + . The likely structure of the ion at m/z 152 is shown in Fig. 5F , based on fragmentation studies of other carbonyl reactive reagents [81] . DeBarber et al. use a reversed phase column (Luna C 8 , 50 Â 2.1 mm, 5 mm particle size) and a water/acetonitrile/ 0.1% formic acid gradient in a 6 min run. Sensitivity was 1 pg oncolumn, and for 4 mL of plasma the lower limit of quantification (LLOQ) was 20 ng/mL. Using this methodology DeBarber et al. found 7a,12a-diHCO to be diagnostic of CTX being elevated by a factor of over 3000 in adults and by a factor of 10 in newborns.
Derivatisation to Girard hydrazones
Perhaps the most popular derivatisation method for LC-MS analysis of oxysterols is derivatisation to Girard hydrazones [82] . This method has been extensively used by Roberg-Larsen and Wilson in Norway [83] [84] [85] , Shevchenko and colleagues in Germany [86] , DeBarber and co-workers in Canada [87, 88] , and Soroosh et al. in the USA [89] and our own group in the UK [29, 30, 32, 33, 51, 52, [90] [91] [92] [93] [94] [95] [96] .
The Girard reagents have been used for decades in steroid analysis [82] . They react with a carbonyl group of a steroid to give a Girard hydrazone (Fig. 5G, step ii) . Girard hydrazones are positively charged on account of the presence of a quaternary amine group, and give enhance steroid solubility in water, a property widely exploited to aid steroid extraction from organic solvents [97] . The charged nature of the Girard hydrazones makes them very suitable for high sensitivity ESI-MS analysis [51, 90, 91, 94, 95, 98] . Many oxysterols have a 3b-hydroxy-5-ene group which can be treated with cholesterol oxidase to give a 3-oxo-4-ene (Fig. 5G , step (i) [99] , suitable for subsequent Girard derivatisation. Once the 3-oxo-4-ene group is in place derivatisation with the Girard reagents is rapid. Oxysterols with a 3b-hydroxy-5a-hydrogen are also oxidised to 3-oxo compounds but the 3-oxo products react with Girard reagents at a slower rate than the corresponding 3-oxo-4-ene compounds [97] . There are two types of Girard reagent generally employed; Girard T (GT) (2-hydrazinyl-2-oxoethyl)-trimethylazanium chloride salt and Girard P (GP) 1-(hydrazinocarbonylmethyl) pyridinium chloride or bromide salt. Our preference is for the GP reagent, although most other groups use the GT reagent. We have exploited enzymatic oxidation and GP derivatisation, in a methodology we call enzyme-assisted derivatisation for sterol analysis (EADSA) in the study of rodent brain, rodent and human CSF and plasma/serum and also cells and medium (Table 1,  Table S1 ) [20, 24, 25, 29, 32, 33, [93] [94] [95] .
Our preference is to extract oxysterols from tissue or fluids into ethanol to which isotope labelled standards are added, centrifuge, and dilute the supernatant to 70% ethanol with water. The solution is passed through a C 18 solid phase extraction (SPE) column; oxysterols and more polar sterols/steroids pass through the column while cholesterol is retained. Oxysterols are then dried and re-dissolved in propan-2-ol then treated with cholesterol oxidase in KH 2 PO 4 buffer. After 60 min at 37 C the reaction is quenched with methanol and GP reagent added with acetic acid catalyst. After overnight incubation at room temperature oxysterols are separated from un-reacted reagent by a second SPE step, this time using an Oasis HLB column. Oxysterols are eluted in methanol.
Our current method of LC-MS analysis exploits reversed phase LC on a Hypersil Gold C 18 column (50 Â 2.1 mm, 1.9 mm particle size) with a methanol/acetonitrile/0.1% formic acid gradient and detection with a ion trap-Orbitrap hybrid high resolution mass spectrometer. Analyte identification is achieved by using exact mass, measured in the high resolution Orbitrap, and by multiple stage fragmentation (MS n ) in the ion trap. A significant advantage of GP derivatisation is that the derivatised oxysterols give distinct fragmentation patterns (Fig. 5G) allowing isomer differentiation. A further advantage is that the method is applicable to down-stream metabolites of oxysterols including cholestenoic and cholenoic acids. The website http://sterolanalysis.org.uk a useful resource displaying MS 3 spectra of GP derivatised sterols. The sensitivity of the method allows oxysterols to be detected at the ng/mL level from 100 mL of plasma and the 30 pg/mL level from 250 mL of CSF. It is also applicable to vitamins D analysis [100] . Roberg-Larsen et al. [83, 84] have adopted a similar approach but using the GT reagent and exploiting a trap column, to remove excess derivatisation reagent, prior to a miniaturised analytical column (Ace C 18 , 150 Â 1 mm or Ace C 18 150 Â 0.1 mm). They have used both micro-LC and nano-LC to improve sensitivity. Using their nano-LC-ESI-MS/MS method they were able to achieve fg detection limits and profile oxysterols in extracts of only 10,000 cells [84] . Ecdysteroids are polyhydroxylated sterols found in insects, and Shevchenko and co-workers have exploited GT derivatisation for the pg detection by LC-ESI-MS/MS of these molecules [86] . 
New developments: Isotope coded derivatisation reagents
A disadvantage of the EADSA strategy as outlined above is that some oxysterols and cholestenoic acids naturally posses a 3-oxo-4-ene function e.g. 7a-HCO, 7aH,3O-CA; this makes them indistinguishable from equivalent molecules oxidised with cholesterol oxidase to contain this function i.e. 7a-HC, 3b,7a-diHCA. To solve this conundrum we divide the oxysterol fraction eluting from the first SPE column into (A) and (B) fractions. The (A) fraction is treated with cholesterol oxidase, while the (B) fraction is not. The (B) fraction will give information about molecules with a natural oxo group, the (A) fraction will give information about molecules oxidised to contain a 3-oxo group and those naturally containing a 3-oxo group. Deconvolution of (B) from (A) reveals the quantity of molecules oxidised to contain a 3-oxo group, i.e. those with a natural 3b-hydroxy group. This procedure requires the recording of two independent LC-MS runs with the obvious knock-on effects on sample throughput. To streamline analysis we have introduced isotope coded derivatisation reagents or quantitative charge-tags [32] .
The GP reagent is straight forward to synthesise as are isotope labelled versions (Fig. 6A) (Fig. 6B) . We now use the concept of differential mass tags in all our analysis (Fig. 7) . The GP skeleton is also applicable to developing isobaric tags where two tags have the same nominal mass but fragment in MS/MS to give ions of different m/z . These fragment ions can then be used for relative quantification of (A) and (B) fractions (Fig. 6A and C) . By generating a quadruplex it is possible to analyse two samples as both (A) and (B) fractions in a single LC-MS/MS run [32] .
Applications of LC-MS for oxysterol analysis
Sterols in plasma from CTX patients
DeBarber et al. have used GP derivatisation without enzymatic oxidation to identify and quantify sterols with a 3-oxo group in plasma of CTX patients [87, 88] . They scaled down the derivatisation method for 10 mL of plasma, omitting cholesterol removal and enzymatic oxidation and removing excess reagent via an HPLC trap column prior to the analytical column [88] . They developed both LC-ESI-MS/MS with MRM and LC-ESI-MS with MS 3 methods for analysis of 7a-HCO, cholest-4-en-3-one and 5a-cholestan-3-one, and LC-ESI-MS 3 also for cholest-4,6-dien-3-one, 7a,12a-diHCO and 7a,12a-dihydroxy-5b-cholestan-3-one. Each of these metabolites is greatly elevated in CTX plasma compared to healthy individuals. We have found similar results when we have analysed CTX plasma, but by including the cholesterol oxidase step we could also show the almost complete absence of (25R)26-HC, 3b-HCA and 3b,7a-diHCA from CTX plasma (Fig. 8 ) [32, 93] .
Unusual oxysterols in plasma
Some patients with CTX and all patients with Smith-LemliOpitz syndrome (SLOS) have high levels of 7-DHC in plasma and tissues [101] . SLOS results from 7-dehydrocholesterol reductase (DHCR7) deficiency (see Fig. 3 ). Recently a new mechanism for the formation of 7-OC was described where 7-DHC is oxidised by CYP7A1 to 7-OC with cholesterol-7,8-epoxide (7,8-EC) as a side product (Fig. 2C) [8] . Using EADSA to profile plasma of SLOS patients we are able to identify 7,8-EC and confirm its absence in plasma from control individuals (Fig. 9) [101] . Further profiling of plasma from patients with SLOS allowed the identification of another unusual oxysterol, 26-hydroxy-8-dehydrocholesterol (26H-8-DHC) first reported in plasma by Wassif et al. [102] , presumably formed from 8-DHC in a CYP27A1 catalysed reaction (Fig. 9) [Griffiths unpublished data]. Honda et al. [103] also identified 26H-8-DHC in liver mitochondrial incubations from a rat model of SLOS.
Oxysterol sulphates and glucuronides in plasma
At the beginning of this section we wrote that a limitation of GC-MS was its inability to detect oxysterols conjugated with glucuronic or sulphuric acids. In contrast, these oxysterols are readily detected without derivatisation by LC-ESI-MS/MS when operated in the negative ion mode [104] . This is illustrated by analysis of plasma from an infant suffering from oxysterol 7a-hydroxylase (CYP7B1) deficiency (Fig. 10) [12] . EADSA introduces the GP group at position 3, so conjugates at this location are not observed with the EADSA method. However, if sulphation or glucuronidation is elsewhere the conjugated oxysterol can be observed (Fig. 10) . These modes of conjugation may be important in different disease states.
Oxysterols in CSF
The levels of oxysterols in CSF are low, however, the cholestenoic acids 3b-HCA, 3b,7a-diHCA and 7aH,3O-CA are far higher (Table 1) [25, 68, 95] . Using our EADSA methodology we not only identify these three acids in CSF, but also find peaks corresponding to down-stream acids (Fig. 11 ). In our earlier publications we tentatively identified the peaks eluting at 2.62 min and 3.53 min in the chromatograms shown in Fig. 11A to correspond to 7a,24S-dihydroxy-3-oxocholest-4-en-26-oic (7a,24-diH,3O-CA) and 7a,25-dihydroxy-3-oxocholest-4-en-26-oic acids (7a,25-diH,3O-CA) [25, 95] . Avanti Polar Lipids have now synthesised these two molecules, and while identification of the peak eluting at 3.53 min as 7a,25-diH,3O-CA is correct, the peak eluting at 2.62 min is not 7a,24-diH,3O-CA. In fact, 7a,24-diH,3O-CA elutes a little earlier than the unknown peak, at 2.04 min. The MS 3 spectrum of the peak eluting at 2.62 min suggest that there is side-chain hydroxylation on the 7aH,3O-CA scaffold presumably at C-22 or C-23. Remaining peaks in the chromatograms shown in Fig. 11A are compatible, according to retention time and MS 3 spectra, with 7a,12a-diH,3O-CA, however, an authentic standard has yet to be synthesised. It should be noted that 7a,25-diH,3O-CA and 7a,12a-diH,3O-CA appear as syn and anti conformers, this is a consequence of derivatisation of an oxo group, and can be seen as a disadvantage, i.e. dilution of ion signal, or an advantage i.e. confirmation of Girard derivatisation.
Internal standards, method validation and quality assurance
Although a number of publications for oxysterol analysis describe validated methods [65, 75] , there are still questions about accuracy of the various assays employed. A critical factor is the purity of the standards used. Although a standard may be "pure" according to TLC, GC-MS, LC-MS or NMR, there may be contaminants which are not visible to the methods used, invalidating the supposed molar concentration of the standard. In collaboration with the Lipid Maps consortium Avanti Polar Lipids Inc have produced a range of high quality quantitative standards of defined concentrations of oxysterols in defined volumes of solvent whose use should reduce inter laboratory variations [69] . Other important factors for accurate quantification that must be considered are the isotopic purity of isotope labelled standards, the use of appropriate standard curves generated under the same conditions as for sample preparation and also the chromatographic resolution of isomers.
To-date there have been two inter-laboratory surveys organised by the European Network for Oxysterol Research (http://oxysterols.com/) where serum samples have been distributed to participating laboratories and oxysterol analysis made [105] . Twenty one laboratories participated in the second survey. Unfortunately, ex vivo cholesterol autoxidation was found to be a problem with highly variable concentrations of 7a-HC, 7b-HC and 7-OC (% coefficient of variation, %CV, 47-129%) returned. This highlights the danger of using any of these metabolites for diagnostic purposes. Even for side-chain oxysterols 24S-HC and (25R)26-HC the %CV for different laboratories was about 60%. Clearly more work is required to standardise analytical methods. The reader is also reminded that a validated method is not necessarily an accurate one and may not give the true answer.
Conclusions
To identify monogenetic disorders of cholesterol biosynthesis and metabolism current LC-MS and GC-MS methods are appropriate, for example CTX is readily diagnosed by an absence or very low levels of (25R)26-HC and an elevation in 7a,12a-diHCO in plasma, while oxysterol 7a-hydroxylase deficiency can be diagnosed by high levels of both (25R)26-HC and 3b-HCA in plasma. However, to compare plasma levels of 24S-HC from patients with AD and controls, where the differences are likely to be only small, methods with low CVs are required. This is particularly relevant where data generated by multiple laboratories is combined. Efforts to harmonise methodologies are ongoing spearheaded by the European Network for Oxysterol Research.
To-date most studies of oxysterols have adopted a targeted approach; however, a non-targeted "lipidomic" approach has been utilised by some. The idea of untargeted lipidomics is not new [106] , but faster and more sensitive instruments now make this work-flow readily available. It is perhaps this aspect of oxysterol analysis where derivatisation strategies are most powerful. GC-MS analysis of TMS ethers using electron ionisation provide spectra rich in structural information allowing the determination of unknown compounds. Similarly, GP derivatisation and LC-MS exploiting MS 3 gives structural information and the identification of unexpected oxysterols.
